Measured by its ability to neutralize GM‑CSF-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.02-0.1 µg/mL in the presence of 10 ng/mL Recombinant Porcine GM‑CSF.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Cell Proliferation Induced by GM-CSF and Neutralization by Porcine GM-CSF Antibody.
Recombinant Porcine GM‑CSF (Catalog # 711-PG) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Porcine GM-CSF (10 ng/mL) is neutralized (green line) by increasing concentrations of Rabbit Anti-Porcine GM-CSF Monoclonal Antibody (Catalog # MAB7111). The ND50 is typically 0.02-0.1 µg/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
GM-CSF was initially characterized as a factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3‑5). It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled alpha ‑helices (8‑10). Mature porcine GM-CSF shares 61%‑72% amino acid sequence identity with canine, feline, human, and rat GM-CSF and 53% with mouse GM-CSF. GM‑CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF R alpha /CD116 and the signal transducing common beta chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 (11, 12). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF R alpha (13). The activity of GM-CSF is species specific between human and mouse (14).
Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509.
Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163.
Cao, Y. (2007) J. Clin. Invest. 117:2362.
Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.
Heuser, M. et al. (2007) Semin. Hematol. 44:148.
Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321.
Kaushansky, K. et al. (1992) Biochemistry 31:1881.
Diederichs, K. et al. (1991) Science 254:1779.
Inumaro, S. and H. Takamatsu (1995) Immunol. Cell Biol. 73:474.
Onetto-Pothier, N. et al. (1990) Blood 75:59.
Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. 87:9655.
Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483.
Shanafelt, A.B. et al. (1991) J. Biol. Chem. 266:13804.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.